EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP)-Reference-Cited by-同舟云学术

EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP)

Published:2018-10 Issue:5 Volume:13 Page:621-629
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Ruiz-Patiño Alejandro, ,Castro Christian David,Ricaurte Luisa María,Cardona Andrés F.^ORCID,Rojas Leonardo,Zatarain-Barrón Zyanya Lucia,Wills Beatriz,Reguart Noemí,Carranza Hernán,Vargas Carlos,Otero Jorge,Corrales Luis,Martín Claudio,Archila Pilar,Rodriguez July,Avila Jenny,Bravo Melissa,Pino Luis Eduardo,Rosell Rafael,Arrieta Oscar

Funder

Foundation for Clinical and Applied Cancer Research

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s11523-018-0594-x/fulltext.html

Reference31 articles.

1. Fidler MM, Bray F, Soerjomataram I. The global cancer burden and human development: a review. Scand J Public Health. 2018;46(1):27–36.

2. Barrón F, Zatarain-Barrón ZL, Cardona AF, Arrieta O. Extending the curve: survival of EGFR-mutated lung cancer patients in the 21st century. J Thorac Dis. 2018;10(3):1265–8.

3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.